Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
   PubMed Web of Science ®Google Scholar
• Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol. 2015;25(3):232–237.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–629.
   PubMed Web of Science ®Google Scholar
• Dellis A, Papatsoris AG. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer. Expert Opin Investig Drugs. 2016;25(6):697–707.
   PubMed Web of Science ®Google Scholar
• Parker C, Gillessen S, Heidenreich A, et al. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v69–77.
   PubMed Web of Science ®Google Scholar
• Cookson MS, Lowrance WT, Murad MH, et al. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015;193:491–499.
   PubMed Web of Science ®Google Scholar
• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–642.
   PubMed Web of Science ®Google Scholar
• Bambury RM, Rathkopf DE. Novel and next-generation androgen receptor-directed therapies for prostate cancer: beyond abiraterone and enzalutamide. Urol Oncol. 2016;34(8):348–355.
   PubMed Web of Science ®Google Scholar
• Shore ND. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother. 2017;18(9):945–952.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: prostate cancer. Version 1. 2017. Last accessed March 8, 2018. Available from: www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
   Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–1503.
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–790.
   PubMed Web of Science ®Google Scholar
• Gupta E, Guthrie T, Tan W. Changing paradigms in management of metastatic castration resistant prostate cancer (mCRPC). BMC Urol. 2014;25:14–55.
   Google Scholar
• Patel JC, Maughan BL, Agarwal AM, et al. Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer. 2013;2013:981684.
   PubMedGoogle Scholar
• Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.
   PubMed Web of Science ®Google Scholar
• Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575–586.
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525–3530.
   PubMed Web of Science ®Google Scholar
• Smith MR, Antonarakis ES, Ryan CJ, et al. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol. 2016;70:963–970.
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Antonarakis ES, Shore ND, et al. Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin Cancer Res. 2017;23(14):3544–3551.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018 Apr 12;378(15):1408–1418.
   PubMed Web of Science ®Google Scholar
• Small EJ, Saad F, Hadaschik B, et al. Patient reported outcomes (PROs). In: SPARTAN, a phase 3, double-blind, randomized study of apalutamide (APA) Plus androgen deprivation therapy (ADT) vs placebo plus ADT in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). San Fransisco (CA): AUA. J Urol 2018; 199(4): e703-e704.
   Google Scholar
• Small EJ, Saad F, Chowdhury S, et al. SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2018; 36(suppl 6S; abstr 161).
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 Mar 27. Identifier NCT02489318, A study of Apalutamide (JNJ-56021927, ARN-509) plus androgen deprivation therapy (ADT) versus ADT in participants with mHSPC (TITAN); 2015 Jul 3 [cited 2018 Jun 5]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02489318
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 Mar 29. Identifier NCT02257736, An efficacy and safety study of Apalutamide (JNJ-56021927) in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in participants with chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC); 2014 Oct 6 [cited 2018 Jun 5]; Available from: https://clinicaltrials.gov/ct2/show/study/NCT02257736
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 Jun 1. Identifier NCT02531516, An efficacy and safety study of JNJ-56021927 (Apalutamide) in high risk prostate cancer subjects receiving primary radiation therapy: ATLAS; 2015 Aug 24 [cited 2018 Jun 5]; Available from: https://clinicaltrials.gov/ct2/show/study/NCT02531516
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 Apr 30. Identifier NCT03009981, A Study of androgen annihilation in high risk biochemically relapsed prostate cancer; 2017 Jan 4 [cited 2018 Jun 5]; Available from: https://www.clinicaltrials.gov/ct2/show/NCT03009981https://clinicaltrials.gov/ct2/show/study/NCT03009981
   Google Scholar
• Maluf FC, Smaletz O, Schutz FAB, et al. Phase II randomized study of abiraterone acetate plus ADT versus apalutamide versus abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). J Clin Oncol. 2018;36(suppl 6S; abstr TPS404).
   Google Scholar
• Emamekhoo H, Barata PC, Magi-Galluzzi C, et al. The association between HSD3B1 genotype and steroid metabolism in normal and prostate cancer (PCa) tissue. J Clin Oncol. 2018;36(suppl 6S; abstr TPS155).
   Google Scholar
• Last accessed May 5, 2018. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm596796.htm
   Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Toren PJ, Gleave ME. Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl. 2013;15:342–349.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Evans CP, Tombal B, et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67:470–479.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–1038.
   PubMed Web of Science ®Google Scholar
• Crona DJ, Milowsky MI, Whang YE. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin Pharmacol Ther. 2015;98:582–589.
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Smith MR, Ryan CJ, et al. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol. 2017;28:2264–2271.
   PubMed Web of Science ®Google Scholar
• Pang X, Wang Y, Chen Y. Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles. Bioorg Med Chem Lett. 2017;27(12):2803–2806.
   PubMed Web of Science ®Google Scholar
• Jentzmik F, Azoitei A, Zengerling F, et al. Androgen receptor aberrations in the era of abiraterone and enzalutamide. World J Urol. 2016;34(3):297–303.
   PubMed Web of Science ®Google Scholar
• Scher HI, Graf RP, Schreiber NA, et al. Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol. 2017;71(6):874–882.
   PubMed Web of Science ®Google Scholar
• Azad AA, Volik SV, Wyatt AW, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. 2015;21:2315–2324.
   PubMed Web of Science ®Google Scholar